Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19

NPO Petrovax

Status and phase: Completed; Phase 3

Conditions: Covid19

Treatments: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector); Biological: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT04540419

Prometheus_Rus

Details and patient eligibility

About

This study is a phase III clinical trial to evaluate efficacy, reactogenicity and safety of the vaccine Ad5-nCoV compared with placebo in volunteers at the age from 18 to 85 years，with the randomized, double-blind design

Full description

A total of 500 healthy adult volunteers at the age from 18 to 85 years will be randomized into two treatment (vaccination) groups in ratio 3:1 by double-blind design.

Volunteers in group 1 (n=375) will be administered a single dose of the vaccine Ad5-nCoV (5E10vp).

Volunteers in group 2 (n=125): will be administered a single dose of placebo. Vaccine Ad5-nCoV or placebo will be administered intramuscularly into the deltoid muscle of the arm at a single dose of 0.5 mL (1 prefilled syringe).

Enrollment: 500 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Presence of signed and dated Informed Consent of volunteer for participation in this study.
2. Men and women at the age of 18-85 years.
3. Bodyweight index 18.5-30.0 kg/m2.
4. The negative result of the test, performed by using PCR, for the presence of SARS-CoV-2 RNA at the stage of screening.
5. Negative result for anti-SARS-CoV-2 IgM and IgG antibodies at the stage of screening.
6. No history of the diagnosis COVID-19.
7. Absence of close contacts with individuals, suspicious for infection SARS-CoV-2, or individuals, in whom the diagnosis COVID-19 was confirmed in laboratory within the last 14 days.
8. Absence of signs of respiratory infection within the last 14 days.
9. Negative results of human immunodeficiency virus (HIV), syphilis, hepatitis B and hepatitis C tests.
10. According to historical data and results of screening examination, a volunteer has no diseases and/or conditions, which in view of Investigator, may influence the safety of volunteer participation and evaluation of study results.
11. Volunteer consent for using safe contraceptive methods through all the study.

Exclusion criteria

1. Positive history of allergy, drug intolerance, including increased sensibility to any of components of the test drug product, as well as the history of serious adverse events in the administration of vaccines (such as allergic reactions, respiratory disturbance, angioedema, stomach pain).
2. Axillary body temperature ≥37.1 °C at the time of screening/randomization.
3. Systolic blood pressure more than 139 mm Hg or less than 100 mm Hg and/or diastolic blood pressure more than 90 mm Hg or less than 60 mm Hg.
4. Clinical significant abnormal laboratory and/or instrumental parameters at screening examination.
5. Acute infectious diseases less than 4 weeks ahead of conduction of screening procedures.
6. Acute and acute course of chronic diseases of GIT, liver, kidneys, cardiovascular, respiratory, nervous and endocrine systems.
7. History of blood and hematopoietic organ diseases.
8. History of diabetes mellitus.
9. History of epilepsy, epileptic syndrome, seizures.
10. History of congenital and acquired immunodeficiency, HIV-infection, lymphoma, leukaemia, systemic lupus erythematosus, juvenile rheumatoid arthritis or other autoimmune diseases.
11. History malignancies.
12. Using immunotropic preparations (immunomodulators, immunostimulators, immunodepressants), antiallergic, cytotoxic preparations for more than 10 sequential days within the last 3 months (except for inhalant and local using glucocorticoids [GCS] or using specified preparations less than 4 weeks ahead of the screening.
13. Using immunoglobulin preparations or blood transfusion less than 3 months ahead of the screening.
14. Using antipyretics (including non-steroidal anti-inflammatory agents and anilides) within 24 hours ahead of randomization.
15. Blood donation or loss (≥450 mL of blood or plasma) less than 3 months ahead of the screening.
16. Vaccination within 6 mon. ahead of screening or reluctance to refuse from the administration of any other vaccine during the study.
17. Anamnestic data/data on alcoholism, narcomania, drug abuse, mental illnesses.
18. Major surgery planned within the nearest 6 months or underwent within the last 6 months ahead of the screening.
19. Carrying out of body piercing procedures, an appendix of tattoo less than 1 month ahead of conduction of screening procedures and through all the study.
20. Pregnancy or breast-feeding period.
21. Participation in another clinical study within 3 months ahead of the screening.
22. Psychic, physical and other reasons, not allowing a volunteer to adhere to conditions and procedures of Study Protocol.
23. Volunteers, who are Clinical Site staff.
24. Other reasons, not allowing the volunteer to take part in this study in view of the study physician.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

500 participants in 2 patient groups, including a placebo group

Ad5-nCoV single dose

Experimental group

Description:

375 subjects, Ad5-nCoV containing 5E10 vp, single dose

Treatment:

Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

Placebo single dose

Placebo Comparator group

Description:

125 subjects, Placebo containing 0 vp, single dose

Treatment:

Biological: Placebo